Professor Andrew Tutt qualified in medicine in 1990. After postgraduate training in General Medicine, he trained in clinical oncology at the The Royal Marsden NHS Foundation Trust before gaining a Doctoral Research Training Fellowship from the Medical Research Council to work in Professor Alan Ashworth’s laboratory at The Institute of Cancer Research, London.
Here, he worked on the then-unknown DNA repair functions of the BRCA2 breast cancer predisposition gene and was awarded his PhD in 2002. In his postdoctoral work as a Clinician Scientist he identified the synthetic lethality between PARP inhibitors and BRCA1/2 mutations with Dr Chris Lord and Professor Alan Ashworth.
He went on to design the Single Agent Proof of Concept Phase I trials and associated DNA repair biomarker studies with the ICR and The Royal Marsden Drug Development Unit, and has since led international Phase II and III trials for BRCA1/BRCA2-associated malignancy.
He cares for women with breast cancer as a Consultant Oncologist in the multidisciplinary Breast Unit at Guy’s and St Thomas’ NHS Foundation Trust. He is Professor of Breast Oncology and Director of the Breast Cancer Now Research Unit at King’s College London and has recently been appointed Director of the Breast Cancer Now Toby Robins Research Centre, Head of the Division of Breast Cancer Research and Professor of Breast Oncology at the ICR.
Professor Tutt has developed a translational laboratory for triple negative breast cancer. He leads a clinical trial programme focusing on TNBC and cancers associated with functional deficiencies in BRCA1 and BRCA2.
He also leads translational laboratories at both the ICR and KCL, studying BRCA1 and BRCA2 associated TNBC forms of breast cancer. Andrew’s group publishes in high impact journals regularly and amongst their latest work they published a new TNBC target, PIM1 kinase, in Nature Medicine in November 2016.
He is Chief Investigator for the recently reported multicentre UKCRN ”Triple Negative Trial” and is Global Study Chair of the ‘OlympiA’ study – an adjuvant PARP inhibitor trial in patients with germline BRCA 1/2 mutations and breast cancer.
He has been a Visiting Professor at British Columbia Cancer Agency, Jean Lubrano Visiting Scholar at Harvard Medical School, and is a member of the St Gallen Early Breast Cancer International Consensus Panel and recently received the Addarii Award for his work in the field of breast and ovarian cancer research.